Disseminated herpes simplex virus (HSV) infection and encephalitis in immunocompromised hosts and neonates is associated with severe illness and death. HSV encephalitis occurs infrequently in immunologically normal adults but, if left untreated, may result in long-term neurologic deficits or death (5) . Antiviral drugs such as acyclovir and vidarabine have improved the outcome of severe HSV infections, but response to therapy is often suboptimal, even if treatment is instituted early in the disease. Mortality in patients with HSV encephalitis treated with antiviral agents approaches 30%, and about 60% of survivors are left with permanent neurologic deficits (16) (17) (18) .
Passive administration of antiviral antibody is effective in the prevention and treatment of HSV infections in animal models (2, 8j 12, 13) . When large doses of HSV antibody are administered with acyclovir or vidarabine early in the course of murine infection, an enhanced therapeutic effect is observed compared with treatment with either agent alone (3, 4, 19 Results of studies by other investigators have also shown that neutralizing activity alone cannot account for all the beneficial effects of passively administered antibody in HSV infections. For example, monoclonal antibodies to surface glycoproteins with no virus-neutralizing activity are protective against murine HSV infection (1) . Direct data on the role of the Fc portion are inconsistent, however, because other investigators have shown that F(ab)2 fragments provide either partial or no protection against infection compared with intact immunoglobulin (9, 11) . It is possible that virus neutralization is important in protection against HSV infection if intact antibody or F(ab)2 fragments are administered very early in the course of infection, before the virus becomes cell associated. Once cellular infection has occurred, however, antibody protection likely involves the binding to cellular HSV-induced glycoprotein antigens and the induction of either complement-dependent cell lysis or antibody-dependent, cell-mediated cytolysis, which are processes that require the Fc portion of the immunoglobulin molecule (10) .
The therapeutic efficacy of IGIV in the mouse model suggests that passive immunotherapy for severe HSV infections may be effective in humans. Clinical trials comparing acyclovir alone to acyclovir in combination with intravenous passive immunotherapy for severe HSV infections may be warranted. Additionally, passive immunotherapy with hightiter HSV antibody may be effective in the prevention of severe HSV infection in neonates exposed to HSV at the time of birth.
